Arrowhead Pharmaceuticals $ARWR

12 de dez. de 2019

ARWR let me be honest this is up 6000% since Dec 2016 & they still don't have phase 3 yet which hold a variety of uncertainties. Anyhow this has been one of the best performing stocks over the past couple years, and I am still a bit hesitant to go against it. I might be early but I still want to get this out as it could be really great opportunity to play the downside.

Personally I would not want to be a buy up here as were hitting major resistance and a choppy trading zone. The monthly chart looks exhausted and ready to take a break. We all know biotechs are crazy, they can run & run and run then on the flip of a dime they crash much harder & faster than they came up.

After having this non-stop run over the past 3 year, I would not be surprised to see a pull-back in the near future even though they had a great 10Q & have plenty of cash from the Janssen deal. Here are some important notes from the 10Q

sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-10k_20190930.htm

We expect that the market price of our Common Stock will continue to fluctuate significantly. We may not continue to generate substantial revenue from the license or sale of our technology for several years, if at all.

We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.
We have incurred net losses since our inception and we expect that our operating losses will continue for the foreseeable future as we continue our drug development and discovery efforts.

Janssen, and the premium JJDC paid on the Company’s common stock during the period.


With this being said I am looking at 6/19/20 $50 Puts
& for more near-term i'm looking at 3/20/20 $50 puts

GLTA

4 de jan. de 2020

Nota

4HR Chart Update 1/3/20

Looking for a move under 59.59